Multiple Myeloma
Conditions
Keywords
myeloma, multiple myeloma, relapsed myeloma, refractory myeloma
Brief summary
Patients with myeloma that has either not responded to previous treatment or has returned after previous treatment will be given a combination of the drugs bendamustine and bortezomib. The bortezomib and bendamustine will be given using an intravenous line (IV) on days 1 and 4 of each cycle, with bortezomib being given first, before each dose of bendamustine. Each cycle will be 28 days long, so patients will be treated the first week of each cycle and then have 3 weeks 'off' (without any treatment). Disease assessments will be performed on day 22 of each cycle. Patients will receive the study drugs until their disease progresses or they are withdrawn from the study. In other studies, bendamustine seems to work well with other drugs. Thus, this study hopes to show that the combination of bortezomib and bendamustine will have activity in relapsed/refractory myeloma.
Detailed description
Patients with relapsed and refractory myeloma who have a measurable paraprotein in the serum or urine or measurable protein by Freelite or measurable disease by plasmacytoma will be given a combination of bendamustine and bortezomib each cycle. Response rate (PR or better after 2 cycles) and duration of response will be assessed. Therapy will be continued until disease progression. The bendamustine would be used in a day 1, day 4 dosing schedule after each dose of bortezomib to take advantage of the chemosensitizing properties of bortezomib. This minimizes the days of treatment to just the first week and allows rebound of blood counts. This will be a phase II trial with dose reduction as necessary. Bendamustine is a drug which appears to be non-cross-resistant with other alkylating agents in vitro and in vivo. Thus, we hypothesize that the combination of bortezomib and bendamustine will have activity in relapsed/refractory myeloma.
Interventions
DRUGBendamustine
On days 1 and 4 of each cycle, bendamustine is given at 90 mg/m\^2 after bortezomib . Patients will be dose reduced to 75 mg/m\^2, and then to 60 mg/m\^2 bendamustine on days 1 and 4 if ANC is not \>1 x 10\^9/L and platelets are not \>50 x 10\^9/L on day 1 of each cycle. Patients will be treated until disease progression after at least one cycle of treatment.
DRUGBortezomib
On days 1 and 4 of each cycle, bortezomib is given first at 1.3 mg/m\^2 followed by bendamustine given at 90 mg/m\^2. Patients will be dose reduced to 75 mg/m\^2, and then to 60 mg/m\^2 bendamustine on days 1 and 4 if ANC is not \>1 x 10\^9/L and platelets are not \>50 x 10\^9/L on day 1 of each cycle. Patients will be treated until disease progression after at least one cycle of treatment.
Sponsors
Cephalon
NYU Langone Health
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Voluntary written informed consent 2. Age 18 years or older 3. Female subject is either post-menopausal or surgically sterilized or willing to use an acceptable method of birth control (i.e., a hormonal contraceptive, intra-uterine device, diaphragm with spermicide, condom with spermicide, or abstinence) for the duration of the study. 4. Male subject agrees to use an acceptable method for contraception for the duration of the study. 5. Diagnosis of multiple myeloma based on standard criteria as follows: Major Criteria * Plasmacytomas on tissue biopsy * Bone marrow plasmacytosis (\>30% plasma cells) * Monoclonal immunoglobulin spike on serum electrophoresis (IgG \>3.5 g/dL or IgA \>2.0 g/dL) or kappa or lambda light chain excretion \>1 g/day on 24 hour urine protein electrophoresis Minor Criteria * Bone marrow plasmacytosis (10 to 30% plasma cells) * Monoclonal immunoglobulin present but of lesser magnitude than given under major criteria * Lytic bone lesions * Normal IgM \<50 mg/dL, IgA \<100 mg/dL, or IgG \<600 mg/dL * Any of the following sets of criteria will confirm the diagnosis of Multiple Myeloma: * Any two of the major criteria or * 1 major plus 2 minor criteria. 6. Measurable disease, defined as a monoclonal immunoglobulin spike (M-Spike) on serum electrophoresis of ≥1 g/dL and/or urine monoclonal immunoglobulin spike of ≥200 mg/24 hours. Non-secretors must have measurable protein by Freelite or measurable disease by plasmacytoma to be eligible. 7. Patients must have refractory myeloma as defined by a greater than 25% increase in their M-protein. They should have progressed on bortezomib. 8. Karnofsky performance status ≥50 9. Patients treated with local radiotherapy with or without a brief exposure to steroids are eligible. Patients who require radiotherapy should have entry to the protocol deferred until the radiotherapy is completed by at least 4 weeks prior to initiation of study drug. 10. Meets the following pretreatment laboratory criteria at baseline (Day 1 of Cycle 1, before study drug administration) * Absolute neutrophil count ≥1 x 10\^3/uL * Platelet count ≥75 x 10\^3/uL * Hemoglobin ≥8.0 g/dL * Calculated or measured CrCL ≥ 40 mL/min * AST or ALT and total bilirubin \< 3 x ULN 11. Echocardiogram with a \>50% Ejection Fraction
Exclusion criteria
Patients meeting any of the following
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Percent Change Response Rate (Partial Response or Better After 2 Cycles) Following Treatment With Bortezomib and Bendamustine | 8 weeks | These criteria included measures of alteration in the natural history of disease, hematologic improvement, cytogenetic response, and improvement in health-related quality of life.The IWG criteria define 4 aspects of responses based on treatment goals: (1) altering the natural history of the disease, (2) cytogenetic response, (3) hematologic improvement (HI), and (4)Quality of Life (QOL) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Toxicity of This Regimen. | Every 4 weeks. | Study toxicity will be measured on an ongoing basis, no less then once per 28-day cycle. |
| Duration of Response of This Regimen. | from initial response to relapse, up to 100 weeks. | Time from response to relapse. Response would have been assessed using European Group for Blood and Marrow Transplantation (EBMT) criteria modified to include near complete remission (nCR) and very good partial remission (VGPR |
Countries
United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Bortezomib and Bendamustine Bendamustine: On days 1 and 4 of each cycle, bendamustine is given at 90 mg/m\^2 after bortezomib . Patients will be dose reduced to 75 mg/m\^2, and then to 60 mg/m\^2 bendamustine on days 1 and 4 if ANC is not \>1 x 10\^9/L and platelets are not \>50 x 10\^9/L on day 1 of each cycle.
Patients will be treated until disease progression after at least one cycle of treatment.
Bortezomib: On days 1 and 4 of each cycle, bortezomib is given first at 1.3 mg/m\^2 followed by bendamustine given at 90 mg/m\^2. Patients will be dose reduced to 75 mg/m\^2, and then to 60 mg/m\^2 bendamustine on days 1 and 4 if ANC is not \>1 x 10\^9/L and platelets are not \>50 x 10\^9/L on day 1 of each cycle.
Patients will be treated until disease progression after at least one cycle of treatment. | 24 |
| Total | 24 |
Baseline characteristics
| Characteristic | Bortezomib and Bendamustine |
|---|---|
| Age, Categorical <=18 years | 0 Participants |
| Age, Categorical >=65 years | 19 Participants |
| Age, Categorical Between 18 and 65 years | 5 Participants |
| Region of Enrollment United States | 24 Participants |
| Sex: Female, Male Female | 10 Participants |
| Sex: Female, Male Male | 14 Participants |
Adverse events
| Event type | EG000 affected / at risk |
|---|---|
| deaths Total, all-cause mortality | 0 / 24 |
| other Total, other adverse events | 0 / 24 |
| serious Total, serious adverse events | 0 / 24 |
Outcome results
Primary
Percent Change Response Rate (Partial Response or Better After 2 Cycles) Following Treatment With Bortezomib and Bendamustine
These criteria included measures of alteration in the natural history of disease, hematologic improvement, cytogenetic response, and improvement in health-related quality of life.The IWG criteria define 4 aspects of responses based on treatment goals: (1) altering the natural history of the disease, (2) cytogenetic response, (3) hematologic improvement (HI), and (4)Quality of Life (QOL)
Time frame: 8 weeks
Population: Participant data was not analyzed because PI left institution
Secondary
Duration of Response of This Regimen.
Time from response to relapse. Response would have been assessed using European Group for Blood and Marrow Transplantation (EBMT) criteria modified to include near complete remission (nCR) and very good partial remission (VGPR
Time frame: from initial response to relapse, up to 100 weeks.
Population: Participant data was not analyzed because PI left institution
Secondary
Toxicity of This Regimen.
Study toxicity will be measured on an ongoing basis, no less then once per 28-day cycle.
Time frame: Every 4 weeks.
Population: Participant data was not analyzed because PI left institution. Data were not available for analysis.